Deepali Pal - Research Associate/Fellow
Although childhood leukaemia can now be successfully treated in 90% of cases, relapse has a very poor outcome and the medicines have side effects that compromise health and long-term quality of life. We have developed a method by which patient-derived leukaemia cells (not cell lines) can now be grown in the laboratory and studied. We are now advancing a drug development technique which will test several medicines on individual patient samples. This project will establish a tool that will rely on patient samples to generate more efficient and less toxic medicines for children with leukaemia.